跳至主要内容
临床试验/ACTRN12615001339549
ACTRN12615001339549招募中3 期

Effect on Migraine Frequency of using Combined Anti-oxidant Therapy: N-acetylcysteine, Vitamin E and Vitamin C (NEC) in adults with frequent migraine: The MIGRANT study.

niversity of Notre Dame Australia0 个研究点目标入组 84 人开始时间: 2015年12月8日最近更新:
适应症

试验速览

阶段
3 期
状态
招募中
发起方
入组人数
84

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Prevention
盲法
Blinded (masking used)

入排标准

年龄范围
18 Years 至 65 Years(—)
性别
All

入选标准

  • 1. Migraine of at least one year’s duration, with onset before 50 years of age.
  • 2. Two-to-eight migraine episodes, and less than six ‘other’ headache types per month, averaged over 12 weeks prior to recruitment.
  • 3. Subjects able to clearly distinguish between migraine and ‘other’ headache types.
  • 4. Cognitive and English language skills allowing completion of headache diaries and self-administration of trial drugs.

排除标准

  • Participation in a concurrent research trial.
  • 1. Chronic daily headaches, according to IHS 2013..Headache Classification Committee of the International Headache Society (IHS).The International Classification of Headache Disorders (3rd Ed) (beta version). Cephalalgia 2013; 33(9): 629–808.
  • 2. Medication-overuse headache and/or other primary headache disorders, according to IHS 2013 criteria.
  • 3. Change in migraine treatment in the twelve weeks prior to, or during the study.
  • 4. Taking 2 or more migraine prevention drugs, .
  • 5. Failure to respond in 2 or more previous migraine prevention trials.
  • 6. Taking NAc, VitE or VitC supplements in the 12 weeks prior to the study.
  • 7. Pregnancy, or risk of pregnancy during the study; female of reproductive age not taking medically prescribed contraception; breast feeding.
  • 8. Adverse reactions to NAc, VitE or VitC preparations; VitC deficiency.
  • 9. Renal dysfunction (eGFR less than 30 ml/min/1.73m2), liver dysfunction (ALT or AST > 300 IU/L).
  • 10. Clinical risks associated with bleeding, coagulopathy, warfarin therapy.
  • 11. Haemochromatosis, glucose-6-phosphate dehydrogenase deficiency.
  • 12. Daily opioid use in the 12 weeks prior to or during the study.
  • 13. Substance abuse, dependence or addiction during the study.
  • 14. Psychosis, bipolar affective disorder.

研究者

发起方
niversity of Notre Dame Australia

相似试验